Pfizer Inc
Dr. Liang joined Optum in 2011. She received an MD and MSc in biostatistics in China. She also earned a PhD in epidemiology at the Brown University School of Public Health. Her previous research focused on cancer and molecular epidemiology with emphasis on genetic and environmental factors and their interactions in the risk of head and neck cancer and prostate cancer. Prior to joining the Epidemiology group, Dr. Liang was a postdoctoral research fellow at the Institute for Technology Assessment at Massachusetts General Hospital and Harvard Medical School where her research focused on using modeling to improve understanding of the impact of lung and esophageal cancer interventions (e.g., prevention, screening and treatment) on population trends in incidence and mortality. Her current work at Optum is in the areas of cancer, diabetes, allergy and substance abuse using claims and EHR data.